Paraneoplastic syndromes in patients with melanoma.
melanoma
paraneoplastic syndrome
Journal
Postepy dermatologii i alergologii
ISSN: 1642-395X
Titre abrégé: Postepy Dermatol Alergol
Pays: Poland
ID NLM: 101168357
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
received:
23
10
2023
accepted:
02
02
2024
medline:
19
7
2024
pubmed:
19
7
2024
entrez:
19
7
2024
Statut:
ppublish
Résumé
Paraneoplastic syndromes are a group of rare clinical conditions characterized by a diverse array of systemic manifestations that arise in association with malignant tumours, often due to the production of bioactive substances by the tumour or an autoimmune response to the tumour. Melanoma, a malignant skin neoplasm originating from melanocytes, has been associated with various paraneoplastic syndromes. This paper provides an overview of the key paraneoplastic syndromes observed in patients with melanoma. Paraneoplastic syndromes in melanoma can manifest with neurological, dermatological, endocrine, haematological, and rheumatological symptoms, among others. Melanoma-associated retinopathy was the most reported paraneoplastic syndrome; this entity is characterized by a spectrum of retinal abnormalities. Paraneoplastic neurological syndromes, such as paraneoplastic encephalitis and paraneoplastic cerebellar degeneration, are among the most frequently reported. The pathophysiology of paraneoplastic syndromes often involves the production of autoantibodies against neuronal or tumour antigens, immune-mediated reactions, or the release of cytokines and growth factors from the tumour. Management strategies for paraneoplastic syndromes associated with melanoma primarily focus on treating the underlying malignancy, which may lead to resolution or improvement of the paraneoplastic manifestations. Immune-modulating therapies, including corticosteroids, intravenous immunoglobulins, and plasmapheresis, may be considered in selected cases to ameliorate symptoms and suppress the autoimmune response. In conclusion, paraneoplastic syndromes in patients with melanoma are a complex and diverse group of clinical entities with a broad range of presentations. Further research is needed to enhance our understanding of the mechanisms and therapeutic options for paraneoplastic syndromes associated with melanoma.
Identifiants
pubmed: 39027696
doi: 10.5114/ada.2024.141114
pii: 54400
pmc: PMC11253314
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
251-261Informations de copyright
Copyright: © 2024 Termedia Sp. z o. o.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.